Myobloc Purple Book BLA 103846

BLA number
103846
Proprietary names
Myobloc
Proper names
rimabotulinumtoxinB
Applicant
Solstice NeuroSciences, LLC
Center
CDER
First observed release
2020-05-01
Latest observed release
2026-06-01
Newest archive release
2026-06-01
FDA patent list
No patents listed in the captured FDA patent list; source updated 2025-06-11
Coverage
Present in newest release

Latest Known Product Presentations#

Product, Proprietary name, Proper name table
ProductProprietary nameProper nameLicense typeStrengthDosage formRoutePresentationMarketingLicensureApprovalPatent list provided
001MyoblocrimabotulinumtoxinB351(a)2,500UNITS/0.5MLInjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2000-12-08
002MyoblocrimabotulinumtoxinB351(a)5,000UNITS/MLInjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2000-12-08
003MyoblocrimabotulinumtoxinB351(a)10,000UNITS/2ML (5,000UNITS/ML)InjectionIntramuscular, IntraglandularSingle-Dose VialRxLicensed2000-12-08

Published Patent List#

No patents for this BLA were listed in the FDA Purple Book patent list captured from the source updated 2025-06-11.

Official Monthly Change Events#

Release, Event, Product table
ReleaseEventProductNameLicense typeStatusApplicant
2021-03-01U001Myobloc351(a)RxSolstice NeuroSciences, LLC
2021-03-01U002Myobloc351(a)RxSolstice NeuroSciences, LLC
2021-03-01U003Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-08-01U001Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-08-01U002Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-08-01U003Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-05-01R001Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-05-01R002Myobloc351(a)RxSolstice NeuroSciences, LLC
2020-05-01R003Myobloc351(a)RxSolstice NeuroSciences, LLC

Observed Product State History#

Release, Product, Name table
ReleaseProductNameLicense typeMarketingLicensureApproval
2020-05-01001Myobloc351(a)RxLicensed2000-12-08
2020-05-01002Myobloc351(a)RxLicensed2000-12-08
2020-05-01003Myobloc351(a)RxLicensed2000-12-08